QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CLYM

QT80Climb Bio, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
11.45
+0.11+0.97%
OverviewShort InterestFilings
CLYMQT80Climb Bio, Inc.·NASDAQ
OverviewShort InterestFilings
11.45+0.97%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own45.44%
Shs Outstand57.26M
Perf Week4.95%
Market Cap773.21MForward P/E-EPS next Y-1.05Insider Trans-0.25%Shs Float-Perf Month18.65%
Enterprise Value765.33MPEG-EPS next Q-0.22Inst Own-Short Float-Perf Quarter64.04%
Income-52810343.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y147.84%
Sales-P/B5.22EPS next Y-20.08%ROA-34.65%Short Interest-Perf YTD186.25%
Book/sh2.79P/C-EPS next 5Y-ROE-31.46%52W High12.48 -8.25%Perf Year854.17%
Cash/sh1.76P/FCF-EPS past 3/5Y-ROIC-40.44%52W Low1.16 887.07%Perf 3Y-
Dividend Est.-EV/EBITDA-14.53Sales past 3/5Y-Gross Margin0.00%Volatility5.41% 5.79%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM49.02%Oper. Margin0.00%ATR (14)0.95Perf 10Y-
Dividend Ex-Date-Quick Ratio27.86Sales Y/Y TTM-Profit Margin0.00%RSI (14)55.57Recom2.00
Dividend Gr. 3/5Y-Current Ratio27.86EPS Q/Q35.48%SMA202.92%Beta2.15Target Price21.67
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5010.79%Rel Volume1.25Prev Close11.34
Employees17LT Debt/Eq-EarningsAug 11SMA200107.94%Avg Volume1.00MPrice11.45
IPO DateAug 10, 2021Option/ShortYes / YesEPS/Sales Surpr.23.08% -Net Debt/EBITDA0.15Volume1,245,850Change0.97%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-11-26ReiteratedBTIGBuy$20
Jun-08-26InitiatedGuggenheimBuy$35
Jun-08-26ReiteratedBTIGBuy$20
May-12-26ReiteratedH.C. Wainwright$15 → $20
May-08-26ReiteratedWedbushOutperform$17
May-06-26ReiteratedRobert W. Baird$12 → $21
May-05-26InitiatedChardanBuy$22
Apr-15-26InitiatedMizuhoOutperform$18
Mar-17-26ReiteratedTruist Financial$17
Mar-10-26ReiteratedRaymond James$25
Latest News
Jun-12-26
Jun-12-2604:25PM
Climb Bio Launches $100M At-The-Market Common Stock Offering Via JefferiesBenzinga
10:19AM
Why Is Climb Bio Stock Gaining Friday?Benzinga
09:59AM
Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price TargetBenzinga
Jun-11-26
Jun-11-2611:41AM
BTIG Maintains Buy on Climb Bio, Raises Price Target to $20Benzinga
07:07AM
Climb Bio Announces Initial Data From Its Ongoing Phase 1b Portion Of Its Phase 1b/2a Study Evaluating Budoprutug In Adults With Primary Immune ThrombocytopeniaBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other211625
Research and Development471415
Other Operating Expense0520
Operating Income-68-82-40
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-8-52-5
Net Income Before Taxes-60-74-35
Income Taxes
000
Consolidated Net Income-60-74-35
Net Income From Continuing Operations-60-74-35
Net Income-60-74-35
EPS (Recurring)-0.88-1.53-1.30
EPS (Basic, Before Extraordinaries)-0.88-1.53-1.30
EPS (Diluted)-0.88-1.53-1.30
EBITDA-60-30-35
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding684827
Market Capitalization272——
Operating Lease Expense
———
Insider Trading Volume
$12.49$11.12$9.75$8.39$7.02● Close Price0.00K219.85K439.69K659.54K879.38KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thomas Stephen BasilDirectorFeb 26 '26Sale7.0116,313114,289154,657Feb 27 12:00 AM
Thomas Stephen BasilDirectorFeb 25 '26Sale7.0033,687235,964170,970Feb 27 12:00 AM
Thomas Stephen BasilDirectorFeb 13 '26Sale5.8110,00058,141204,657Feb 17 12:00 AM
Thomas Stephen BasilDirectorFeb 12 '26Sale5.2390,000470,988214,657Feb 17 12:00 AM
RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:Jan 05 '26Buy3.507,11124,8893,403,429Jan 07 12:00 AM
RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:Dec 12 '25Buy2.86101,462290,1813,396,318Dec 15 12:00 AM
RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:Dec 11 '25Buy2.18213,099464,5563,294,856Dec 15 12:00 AM
Brennan AoifePresident and CEOJun 30 '25Sale1.2220,61825,15448,132Jul 01 12:00 AM
Brennan AoifePresident and CEOJun 27 '25Option Exercise0.00137,5000206,250Jul 01 12:00 AM
Thomas Stephen BasilDirectorJun 27 '25Option Exercise0.0050,1880204,282Jul 01 12:00 AM
Pimblett EmilySVP, Finance & CAOJun 20 '25Sale1.241,2421,54018,888Jun 20 12:00 AM
Pimblett EmilySVP, Finance & CAOJun 18 '25Option Exercise0.0010,000020,130Jun 20 12:00 AM
Thomas Stephen BasilDirectorMar 27 '25Option Exercise0.0050,1860179,188Mar 27 12:00 AM
Pimblett EmilySVP, Finance & CAOMar 20 '25Sale1.311,1991,57115,130Mar 20 12:00 AM
Pimblett EmilySVP, Finance & CAOMar 18 '25Option Exercise0.0010,000020,000Mar 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR